Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809610 | 0.81 | HTR1A (0.57) | HTR2AHTR1ADRD2CYP2D6ADRA1B | |
| SCHEMBL7815509 | 0.78 | HTR2A (0.61) | HTR2ADRD4HTR1ADRD2ADRA1B | |
| SCHEMBL4299920 | 0.74 | HTR2A (0.57) | HTR2ADRD4HTR1ADRD2ADRA1B | |
| SCHEMBL4438394 | 0.74 | HTR2A (0.56) | HTR2ADRD4HTR1ADRD2ADRA1B | |
| SCHEMBL4307343 | 0.73 | KDR (0.42) | HTR1ADRD2RAB9A | |
| SCHEMBL4910280 | 0.73 | ADRA1B (0.63) | HTR1ACYP2D6ADRA1BSIGMAR1ADRA1A | |
| SCHEMBL3197906 | 0.71 | CYP2D6 (0.63) | HTR2ADRD4HTR1ADRD2CYP2D6 | |
| SCHEMBL7653085 | 0.67 | CYP2D6 (0.70) | HTR2ADRD4HTR1ADRD2CYP2D6 | |
| SCHEMBL8828407 | 0.66 | ADRA1B (0.48) | HTR2AHTR1ADRD2CYP2D6ADRA1B | |
| SCHEMBL946834 | 0.65 | SIGMAR1 (0.59) | HTR2AHTR1ADRD2CYP2D6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | HTR2A 46/4885DRD4 13/4885HTR1A 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.